UC Davis Health Clinical Studies

A Study of Outcomes in Patients With Complex Trauma and Significant Injuries

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

You are being invited to join a research study. This study is funded by the Department of Defense (DoD). The purpose is to gain a better understanding of patient outcomes after significant injury. To do so, the study team will examine and compare characteristics across patient populations (i.e. with different injuries). Some of the patient characteristics we will be looking at will be found in your medical record. Others will include information we collect from left over (remnant) blood samples.

Other Study
Any, age 18 years or older

An Experimental Combination Study of S1803, Daratumumab/rHuPh20 +/- Lenalidomide for Multiple Myeloma (MM)

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

This study is being done to answer the following questions: 1. Will adding the experimetnal drug daratumumab/rHuPH20 to the usual maintenance treatment help multiple myeloma patients survive longer? 2. For patients who have no evidence of multiple myeloma in their bone marrow, should maintenance therapy be stopped after 2 years? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your multiple myeloma. The usual approach is defined as care most people get for multiple myeloma. The usual approach for patients who are not in a study is treatment with an FDA approved multiple myeloma drug (such as lenalidomide) after stem cell transplant.

Drug study, Phase 3
Any, age 18 to 75 years old

A Study of Experimental Ataluren for Nonsense Mutation Dystrophinopathy (nmDBMD)

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

This study is for boys with Duchenne/Becker muscular dystrophy (DMD/BMD). The condition studied in this study is caused by a nonsense mutation in the dystrophin gene. Participants must have been treated with ataluren in a past clinical trial or treatment plan. The main goal of this study is to learn whether experimental ataluren is safe for patients with DMD/BMD. Experimental means that ataluren is not approved by the FDA to be used except in a research study. The FDA has allowed the use of ataluren in this study. We hope to find out if it could one day be made more widely available for doctors to prescribe it for patients with DMD/BMD.

Drug study, Phase 3
Male, age -1 years or older

A Study of the Experimental Prevena™ device (Incisional Negative Pressure Wound Therapy) for Soft Tissue Sarcoma Wounds

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

Patients with sarcomas (tumor in bone or soft tissue) who receive radiation before surgery have a greater chance of complications in wound healing. This research study will test a wound dressing called Negative Pressure Wound Therapy (NPWT). NPWT is a wound sponge attached to a gentle suction device. It is more effective at preventing infection of the surgical wound than standard dry gauze wound dressing. The Prevena™ device (NPWT) is FDA approved for use on incisions. This will be considered the investigational dressing. The NPWT device is a foam sponge that is placed over the incision after surgery, and provides a low pressure gentle suction on the wound. It is sealed with an adhesive dressing. The traditional standard dry gauze dressing will be considered the control dressing for this study

Device study
Any, age 18 years or older

A Long-Term Safety and Tolerability Study of Experimental Givinostat in Duchenne Muscular Dystrophy

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

This study will test the long-term safety and effectiveness of the experimental medicine Givinostat. It will be given to patients with Duchenne Muscular Dystrophy (DMD). This long-term study is for patients who have already participated in a study with Givinostat. It provides the opportunity for them to continue treatment. This study is for patients with Duchenne Muscular Dystrophy currently taking experimental Givinostat.

Drug study, Phase [2, 3]
Male, age 7 years or older

A Study of Experimental Blood Derived Autologous Angiogenic Cell Precursor (type of stem cell) Therapy for Critical Limb Ischemia

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

Peripheral Artery Disease (PAD) is a common, progressive circulatory disease. It sometimes advances to Critical Limb Ischemia (CLI). CLI symptoms can be painful and lead to sores and in some cases amputation. This study will test the safety and effectiveness of injecting Angiogenic Cell Precursors (ACPs) into the muscles of your leg and foot. ACPs are specific stem cells collected from your blood. This experimental study treatment will be used to relieve symptoms of Critical Limb Ischemia.

Biological study, Phase 2
Any, age 18 years or older
Loading